High Price for U.K. Lad's Cancer Battle
Posted on: Saturday, 20 January 2007, 21:00 CST
The parents of a 5-year-old London boy have moved him to New York to undergo specialized cancer treatments not available in the United Kingdom.
In a desperate move across the pond, two Scotland Yard detectives moved their ailing son, Jack Brown -- who had been given only a 20-percent chance of survival without a certain antibody treatment available at Memorial Sloan-Kettering Cancer Center, the New York Daily News reported.
We might still lose our child, Yvonne Brown, 39, told the newspaper. But his chances have increased tremendously by him being here.
Fundraising efforts in Britain made the family's trip to New York possible, but serious complications have run up their tab by an additional $750,000.
The family is residing in the Ronald McDonald House, which provides shelter for young cancer patients' families, while they try to raise $350,000, which will then be matched by an anonymous benefactor.
Further information about donating funds for the sick child can be found at jackbrownappeal.org.
Source: United Press International
Related Articles
- Manhattan Diagnostic Radiology First in New York City to Offer Positron Emission Mammography (PEM) Scanner From Naviscan in the Fight Against Breast Cancer
- Radiation Oncology Associates of New York Becomes First in New York to Offer Patients a New, Faster Radiotherapy for Treating Cancer
- New York Business Group on Health Presents Conference on How to Cope With Cancer in the Workplace
- Fitch Affirms Memorial Sloan-Kettering Cancer Center's (New York) Bonds at 'AA'; Outlook Stable
- BSD Medical Presents Cutting-Edge Cancer Treatment Systems at New York Oncology Congress
- Dolores Hopper Takes Helm at York Cancer Care Center
- New York Receives 'Very Good' Rating, But Cervical Cancer Report Cites Gaps
- Breast Cancer Doesn't Wait for a Mammogram, Neither Can the Women of New York!
- Community Care Physicians of Latham, New York Deliver Ultra-Precise Image-Guided Radiotherapy Treatments for Prostate Cancer Patients
- Phase I Clinical Trial for Advanced Colon and Pancreatic Cancer Opens in New York Using Rexin-G, the World's First Tumor-Targeted Gene Delivery Vector
 |
 |
User Comments (0)
RSS Feeds